A 38-year-old woman from Mumbai with a 3-year history of seropositive rheumatoid arthritis (RF and anti-CCP positive) presents with progressive joint destruction despite conventional DMARD therapy. A synovial biopsy from an inflamed knee joint is performed. Histological examination shows hyperplastic synovium with a dense infiltrate of CD4+ T cells, B cells, and plasma cells arranged in lymphoid aggregates with germinal centre-like structures. Numerous activated macrophages and fibroblasts are also present. Which of the following best describes the immunopathological process occurring in this synovial tissue?

Question

Accepted Answer

D. Type III hypersensitivity reaction with immune complex deposition, complement activation, and recruitment of inflammatory cells to perpetuate chronic synovitis. ## Immunopathological Classification of Rheumatoid Arthritis

### RA as a Type III Hypersensitivity Reaction

**Key Point:** Rheumatoid arthritis is fundamentally a **Type III (immune complex-mediated) hypersensitivity reaction** with a secondary Type IV (cell-mediated) component. The synovial inflammation is driven by immune complex deposition and complement activation.

### Pathological Sequence in RA

```mermaid
flowchart TD
  A[B cell activation by Th17/Tfh cells]:::outcome --> B[Production of RF and anti-CCP antibodies]:::action
  B --> C[Formation of immune complexes]:::outcome
  C --> D[Deposition in synovial membrane and fluid]:::action
  D --> E[Complement activation via classical pathway]:::action
  E --> F[C3a and C5a generation]:::outcome
  F --> G[Recruitment of neutrophils and macrophages]:::action
  G --> H[Synovial inflammation and cytokine release]:::action
  H --> I[TNF-α, IL-6, IL-17 production]:::outcome
  I --> J[Perpetuation of B and T cell activation]:::action
  J --> K[Chronic synovitis and pannus formation]:::urgent
```

### Histological Features Explained

| Feature | Mechanism | Hypersensitivity Type |
|---------|-----------|----------------------|
| Hyperplastic synovium | Chronic inflammation and angiogenesis | Type III |
| Dense CD4+ T cell infiltrate | Th1 and Th17 cells recruited by chemokines (C5a, CXCL10) | Type III + Type IV |
| B cells and plasma cells | Antibody production (RF, anti-CCP) | Type III |
| Germinal centre-like structures | Local B cell activation and antibody class switching | Type III |
| Activated macrophages | Recruited by C5a and activated by TNF-α | Type III |
| Fibroblasts | Activated by TNF-α and IL-17; produce MMPs | Type III |

**High-Yield:** The presence of **germinal centre-like structures** in the synovium indicates ongoing B cell activation and antibody production within the joint — a hallmark of Type III hypersensitivity.

### Why Type III, Not Type II?

**Key Point:** Type II hypersensitivity involves antibody binding directly to cell surface antigens (e.g., Graves' disease, pemphigus). In RA, the antibodies (RF, anti-CCP) form **soluble immune complexes** that deposit in tissues and activate complement — the definition of Type III hypersensitivity.

**Mnemonic:** **IIIC** — Type III = **I**mmune complexes, **I**n tissues, **I**nflammation, **C**omplement activation.

### The Secondary Type IV Component

While the primary mechanism is Type III, RA also has a Type IV (cell-mediated) component:
- **Th1 cells** produce IFN-γ, activating macrophages
- **Th17 cells** produce IL-17, activating fibroblasts and osteoclasts
- **CD8+ T cells** may contribute to synovial inflammation

However, the **dominant and initiating** mechanism is Type III (immune complex-mediated).

### Clinical Correlations

**Clinical Pearl:** The presence of **high-titre RF and anti-CCP antibodies** in this patient's serum indicates active immune complex formation. The **synovial biopsy findings** (lymphoid aggregates, germinal centres, activated macrophages) confirm local immune complex deposition and complement-driven inflammation.

**Warning:** Do not confuse RA with:
- **Type II hypersensitivity:** No direct antibody-to-cell-surface binding in RA
- **Type IV hypersensitivity:** While present, it is secondary to immune complex-mediated inflammation
- **Type I hypersensitivity:** No IgE involvement; mast cells are not the primary effectors

[cite:Robbins 10e Ch 6; Harrison 21e Ch 329]

Answer

A. Type I hypersensitivity reaction with mast cell degranulation and release of inflammatory mediators

Answer

B. Type IV hypersensitivity reaction with Th1-mediated macrophage activation and granuloma formation

Answer

C. Type II hypersensitivity reaction mediated by IgG immune complexes and complement-dependent cytotoxicity of synovial cells

Explanation

Immunopathological Classification of Rheumatoid Arthritis

RA as a Type III Hypersensitivity Reaction

Pathological Sequence in RA

Histological Features Explained

Why Type III, Not Type II?

The Secondary Type IV Component

Clinical Correlations

Practice similar questions

Join our NEET PG community

Feature	Mechanism	Hypersensitivity Type
Hyperplastic synovium	Chronic inflammation and angiogenesis	Type III
Dense CD4+ T cell infiltrate	Th1 and Th17 cells recruited by chemokines (C5a, CXCL10)	Type III + Type IV
B cells and plasma cells	Antibody production (RF, anti-CCP)	Type III
Germinal centre-like structures	Local B cell activation and antibody class switching	Type III
Activated macrophages	Recruited by C5a and activated by TNF-α	Type III
Fibroblasts	Activated by TNF-α and IL-17; produce MMPs	Type III